Currently, Baricitinib is FDA-approved (at 2 mg daily dose) for rheumatoid arthritis (RA) patients failing Tumor Necrosis Factor (TNF) inhibitors [148,149,150]. This evidence concerns the gene TNF and rheumatoid arthritis.